Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Sep. 30, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 30,133,213	$ 24,838,567
Accounts receivable	327,375	67,797
Prepaid expenses	1,267,717	867,363
Other current assets	640,117	1,359,638
Short term investments	46,400,176	40,769,539
TOTAL CURRENT ASSETS	78,768,598	67,902,904
Property and equipment, net	13,935,425	15,513,019
Intangible assets, net	18,764,010	20,464,439
Other assets	141,918	141,918
TOTAL ASSETS	111,609,951	104,022,280
CURRENT LIABILITIES
Accounts payable	2,806,098	4,076,514
Accrued expenses	5,043,087	4,564,507
Accrued payroll and benefits	3,937,605	3,399,679
Deferred rent	307,334	440,580
Deferred revenue	600	5,269,741
Derivative liabilities		695,114
Note Payable	223,820	208,506
Other current liabilities	46,407	46,407
TOTAL CURRENT LIABILITIES	12,364,951	18,701,048
LONG-TERM LIABILITIES
Deferred rent, net of current portion	1,702,801	1,929,052
Note Payable, net of current portion	2,101,198	2,325,018
Other non-current liabilities	200,000	200,000
TOTAL LONG-TERM LIABILITIES	4,003,999	4,454,070
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:
Common stock, $0.001 par value; 145,000,000 shares authorized; 88,505,302 and 74,785,726 shares issued and outstanding as of September 30, 2018 and September 30, 2017, respectively	180,875	167,155
Additional paid-in capital	582,902,694	514,037,301
Accumulated other comprehensive income (loss)	(21,564)	33,232
Accumulated deficit	(487,265,816)	(432,815,338)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	95,796,189	81,422,350
Noncontrolling interest	(555,188)	(555,188)
TOTAL STOCKHOLDERS’ EQUITY	95,241,001	80,867,162
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 111,609,951	$ 104,022,280